Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 198
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AC264F954CDEN
Leaflet:

Download PDF Leaflet

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
  • The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects
  • The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Attention Deficit Hyperactivity Disorder (ADHD) Overview
Therapeutics Development
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies
Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
Alcobra Ltd
Amarantus Bioscience Holdings, Inc.
APeT Holding BV
Arbor Pharmaceuticals, LLC
BCWorld Pharm Co. Ltd.
BioLite, Inc.
Collegium Pharmaceutical, Inc.
Curemark, LLC
DURECT Corporation
Egalet Corporation
Eli Lilly and Company
Ensysce Biosciences Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Highland Therapeutics, Inc.
Integrative Research Laboratories Sweden AB
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
KemPharm, Inc.
Luc Therapeutics, Inc.
Medgenics, Inc.
Merck & Co., Inc.
Neos Therapeutics, Inc.
NeuroDerm Ltd.
Neurovance, Inc.
NLS Pharma Group
Noven Pharmaceuticals, Inc.
P2D Bioscience
Polleo Pharma Limited
Reviva Pharmaceuticals Inc.
Shire Plc
Sunovion Pharmaceuticals Inc.
Supernus Pharmaceuticals, Inc.
Taisho Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
TRImaran Pharma, Inc.
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(nicotine + opipramol hydrochloride) - Drug Profile
AR-08 - Drug Profile
BCWPE-003 - Drug Profile
BLI-1008 - Drug Profile
BNC-375 - Drug Profile
CB-8411 - Drug Profile
centanafadine IR - Drug Profile
centanafadine SR - Drug Profile
CM-4612 - Drug Profile
CTX-1301 - Drug Profile
CTX-1302 - Drug Profile
dasotraline hydrochloride - Drug Profile
dextroamphetamine - Drug Profile
dextroamphetamine MR - Drug Profile
edivoxetine hydrochloride - Drug Profile
Egalet-003 - Drug Profile
eltoprazine - Drug Profile
etiguanfacine - Drug Profile
fasoracetam - Drug Profile
guanfacine hydrochloride ER - Drug Profile
histamine dihydrochloride - Drug Profile
HTL-1071 - Drug Profile
INV-107 - Drug Profile
INV-170 - Drug Profile
IRL-752 - Drug Profile
ITI-214 - Drug Profile
KP-415 CR - Drug Profile
lisdexamfetamine dimesylate - Drug Profile
mazindol - Drug Profile
Metadoxine ER - Drug Profile
methylphenidate hydrochloride ER - Drug Profile
methylphenidate hydrochloride MR - Drug Profile
methylphenidate hydrochloride SR - Drug Profile
methylphenidate hydrochloride XR - Drug Profile
MGS-0028 - Drug Profile
molindone hydrochloride ER - Drug Profile
niacinamide CR - Drug Profile
NLS-3 - Drug Profile
NLS-4 - Drug Profile
NT-0201 - Drug Profile
P-001 - Drug Profile
PBF-509 - Drug Profile
PD-2005 - Drug Profile
PD-3044 - Drug Profile
PFR-08001 - Drug Profile
PFR-8026 - Drug Profile
RP-5063 - Drug Profile
SHP-465 - Drug Profile
Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile
Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder - Drug Profile
Small Molecules to Inhibit Dopamine Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile
Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile
Synthetic Peptide to Antagonize D2 for ADHD - Drug Profile
TS-141 - Drug Profile
Vaccine for CNS Disorders - Drug Profile
viloxazine hydrochloride ER - Drug Profile
vortioxetine hydrobromide - Drug Profile
VU-0238429 - Drug Profile
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2016
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Investigation by Universities/Institutes, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co. Ltd., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioLite, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Egalet Corporation, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Limited, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Medgenics, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co., Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Polleo Pharma Limited, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by TRImaran Pharma, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd.1), H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd.2), H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd.3), H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd.4), H2 2016
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2016
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Alcobra Ltd
Amarantus Bioscience Holdings, Inc.
APeT Holding BV
Arbor Pharmaceuticals, LLC
BCWorld Pharm Co. Ltd.
BioLite, Inc.
Collegium Pharmaceutical, Inc.
Curemark, LLC
DURECT Corporation
Egalet Corporation
Eli Lilly and Company
Ensysce Biosciences Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Highland Therapeutics, Inc.
Integrative Research Laboratories Sweden AB
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
KemPharm, Inc.
Luc Therapeutics, Inc.
Medgenics, Inc.
Merck & Co., Inc.
Neos Therapeutics, Inc.
NeuroDerm Ltd.
Neurovance, Inc.
NLS Pharma Group
Noven Pharmaceuticals, Inc.
P2D Bioscience
Polleo Pharma Limited
Reviva Pharmaceuticals Inc.
Shire Plc
Sunovion Pharmaceuticals Inc.
Supernus Pharmaceuticals, Inc.
Taisho Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
TRImaran Pharma, Inc.
Skip to top


Ask Your Question

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: